evidence: The United Kingdom formally left the European Union on 31 January 2020. Following the end of the transitional period, the Trade and Cooperation Agreement – and the Protocol on Northern Ireland – was implemented on 1 January 2021. The HPRA continues to engage with all stakeholders to minimise the impact of Brexit and to ensure the supply of health products for the Irish market. [...] The European Commission has put forward proposals to ensure the continued long-term supply of medicines from Great Britain to Northern Ireland and to address outstanding supply concerns in Ireland, Cyprus and Malta. The existing derogations for human and veterinary medicinal products impacted by Brexit will be extended until the end of 2022, or until a legislative proposal is put in place. [...] This notice outlines that due to the historical dependence of Ireland, Malta, Cyprus and Northern Ireland on medicines supplied from Great Britain, in the exceptional cases where additional time is required to transfer certain functions to EU/EEA, and in the exceptional circumstance of a global pandemic, an additional period of up to one year (Jan 2021 to 31 Dec 2021) to comply with aspects of the Union’s acquis, has been agreed.